Arrowhead Pharmaceuticals Announces closing of collaboration agreement with Amgen

23-Nov-2016 - USA

Arrowhead pharmaceuticals, Inc. (NASDAQ: ARWR) announced that the license and collaboration agreement between Arrowhead and Amgen covering the novel RNAi ARC-LPA program has closed, following early termination of the waiting period.


ARC-LPA is designed to reduce production of apolipoprotein A, a key component of lipoprotein(a), which has been genetically linked with increased risk of cardiovascular diseases, independent of cholesterol and LDL levels. ARC-LPA is Arrowhead’s first drug candidate to use a subcutaneously administered delivery construct.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances